Utah Retirement Systems lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 4.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 120,322 shares of the conglomerate’s stock after selling 5,300 shares during the quarter. Utah Retirement Systems’ holdings in Danaher were worth $27,082,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in DHR. Sterling Investment Advisors Ltd. acquired a new stake in Danaher during the 1st quarter worth $25,000. RMR Wealth Builders acquired a new position in shares of Danaher during the 4th quarter valued at about $26,000. Ellis Investment Partners LLC boosted its position in shares of Danaher by 72.6% during the 1st quarter. Ellis Investment Partners LLC now owns 126 shares of the conglomerate’s stock valued at $28,000 after acquiring an additional 53 shares during the last quarter. SOA Wealth Advisors LLC. acquired a new position in shares of Danaher during the 4th quarter valued at about $29,000. Finally, Burleson & Company LLC acquired a new position in shares of Danaher during the 1st quarter valued at about $40,000. 77.50% of the stock is currently owned by institutional investors.
NYSE:DHR traded up $5.19 on Thursday, reaching $284.99. 42,039 shares of the company’s stock were exchanged, compared to its average volume of 2,174,544. The company has a quick ratio of 1.70, a current ratio of 2.05 and a debt-to-equity ratio of 0.55. The stock has a market cap of $203.28 billion, a price-to-earnings ratio of 44.06, a price-to-earnings-growth ratio of 1.77 and a beta of 0.69. The business has a fifty day simple moving average of $261.17. Danaher Co. has a 52-week low of $190.34 and a 52-week high of $287.00.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 30th. Stockholders of record on Friday, June 25th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date is Thursday, June 24th. Danaher’s dividend payout ratio is presently 13.31%.
Several research analysts have recently weighed in on the stock. KeyCorp boosted their price target on shares of Danaher from $280.00 to $315.00 and gave the company an “overweight” rating in a research report on Friday, April 23rd. Zacks Investment Research cut shares of Danaher from a “hold” rating to a “sell” rating and set a $241.00 price target on the stock. in a research report on Friday, April 9th. Barclays boosted their price objective on shares of Danaher from $300.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday, July 13th. Citigroup boosted their price objective on shares of Danaher from $275.00 to $315.00 in a report on Friday, April 23rd. Finally, William Blair restated an “outperform” rating on shares of Danaher in a report on Monday, April 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $280.27.
In other news, Director Teri List sold 4,548 shares of the business’s stock in a transaction dated Thursday, May 27th. The stock was sold at an average price of $255.10, for a total transaction of $1,160,194.80. Following the completion of the transaction, the director now directly owns 20,862 shares of the company’s stock, valued at $5,321,896.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Robert S. Lutz sold 6,006 shares of the company’s stock in a transaction that occurred on Friday, May 21st. The shares were sold at an average price of $254.75, for a total value of $1,530,028.50. Following the completion of the transaction, the chief accounting officer now directly owns 18,476 shares of the company’s stock, valued at $4,706,761. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,165 shares of company stock valued at $9,051,818. Corporate insiders own 11.40% of the company’s stock.
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines.
Read More: What is the NASDAQ Stock Market?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.